Do Minor Cannabis Cannabinoids Like CBN Ease Dementia Anxiety?

PostedMarch 10, 2026

UpdatedMarch 10, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As cannabis research expands, attention has turned to minor cannabinoids such as cannabinol (CBN), cannabigerol (CBG), and cannabichromene (CBC). These compounds occur naturally in the cannabis plant in much smaller amounts than THC or CBD. Some laboratory studies suggest they may have calming or neuroprotective properties, leading to growing interest in whether they could help with anxiety and agitation in dementia.

What The Research Shows

So far, there is no robust clinical evidence that CBN or other minor cannabinoids reduce anxiety in dementia. Most data come from preclinical studies in animals or laboratory models.

CBN is a mildly psychoactive compound formed when THC ages or oxidises. It has been studied for potential sedative and anti-inflammatory effects. A 2021 review in Frontiers in Pharmacology suggested that CBN may act on CB1 and CB2 receptors involved in anxiety regulation, but human trials are lacking.

Early human research on CBD-rich extracts sometimes includes trace CBN or CBG, yet it remains unclear whether these minor cannabinoids add therapeutic value.

What The Guidelines Say

According to NICE guidance NG144 (updated 2025), cannabis-based medicinal products (CBMPs) should not be prescribed for dementia-related anxiety or agitation outside of research trials. The NHS emphasises that only a few cannabis-derived medicines are licensed in the UK, and none contain CBN, CBG, or CBC.

The World Health Organization (WHO) has reviewed CBD but not CBN or other minor cannabinoids, meaning there is currently no recognised medical use or safety profile for these compounds in dementia care.

Expert Commentary

The Alzheimer’s Society notes that while cannabinoids are being studied for behavioural symptoms, evidence for anxiety control remains weak. The Royal College of Psychiatrists and Mayo Clinic similarly caution that unlicensed cannabis compounds, including CBN, should not be used for dementia symptoms outside monitored research.

Clinical Bottom Line

CBN and other minor cannabinoids (CBG, CBC) have not been clinically tested for dementia anxiety.

Evidence is limited to animal or laboratory studies, not human trials.

NICE and NHS do not recommend their use for behavioural or psychological symptoms.

No licensed CBN-containing medicines are available in the UK.

Future research may clarify whether these compounds have a role in dementia care.

About AlleviMed

If you’re exploring whether medical cannabis could be appropriate for a loved one, the best next step is to speak with a specialist clinician experienced in both neurology and cannabinoid medicine. Services like AlleviMed (launching soon) can provide eligibility consultations to help patients understand whether cannabis-based treatment might be legally and clinically suitable for their condition.

Takeaway

Minor cannabinoids like CBN and CBG are biologically interesting but remain experimental. There are currently no human trials showing they reduce dementia-related anxiety. Regulatory bodies such as NICE and NHS recommend limiting cannabinoid use to research until more evidence is available.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.